Showing results (31-40 of 76) with videos related to
Sort By:
Pageof 8
Therapeutic Drug Monitoring|May 29, 2004
Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypesScott R Penzak, Jean M Shen, Raul M Alfaro, et al.Mycoses|October 9, 2014
Emerging drugs and vaccines for candidemiaBrad Moriyama, Lori A Gordon, Matthew McCarthy, et al.Current Fungal Infection Reports|February 27, 2016
Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of VoriconazoleBrad Moriyama, Sameer Kadri, Stacey A Henning, et al.Current Medical Research and Opinion|January 22, 2008
Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjectsSarah M Robertson, Richard T Davey, Jocelyn Voell, et al.Journal of Clinical Psychopharmacology|August 13, 2002
Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteersScott R Penzak, Yuen Yi Hon, Walter D Lawhorn, et al.Journal of Clinical Pharmacology|April 19, 2008
Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactionsScott R Penzak, Kristin H Busse, Sarah M Robertson, et al.European Journal of Clinical Pharmacology|December 17, 2011
Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavirMichael W Jann, Vicky Spratlin, Kathryn Momary, et al.Archives of Neurology|June 15, 2007
Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxiaNicholas A Di Prospero, Charlotte J Sumner, Scott R Penzak, et al.Antimicrobial Agents and Chemotherapy|May 26, 2006
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipientsPaul O Gubbins, Gopal Krishna, Angela Sansone-Parsons, et al.Mycoses|December 1, 2011
Adverse interactions between antifungal azoles and vincristine: review and analysis of casesBrad Moriyama, Stacey A Henning, Janice Leung, et al.Pageof 8